Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.

BMC cancer - 27 Jul 2016

Whicker Margaret E, Lin Z Ping, Hanna Ruth, Sartorelli Alan C, Ratner Elena S

Abstract excerpt

BACKGROUND: Platinum resistance is a major obstacle in the treatment of epithelial ovarian cancer (EOC). Activation of the AKT pathway promotes platinum resistance while inhibition of AKT sensitizes chemoresistant cells. Patients with BRCA mutant EOC, and thus a defect in the homologous recombination (HR) repair pathway, demonstrate greater clinical response to platinum and olaparib therapy than patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Ovarian Epithelial
Share to Cisplatin
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heterocyclic Compounds, 3-Ring

Share to Neoplasms, Glandular and Epithelial

Share to Phthalazines

Share to Piperazines

Share to Proto-Oncogene Proteins c-akt

Source

Open in PubMed Open full text

Identifiers

PMID: 27465688
DOI: 10.1186/s12885-016-2598-1
PMCID: PMC4964088

Genes

BRCA2
BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.PMID 27465688Read ↗

DNA-PK Mediates AKT Activation and Apoptosis Inhibition in Clinically Acquired Platinum ResistanceSemantic proximity Read ↗

Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitroSemantic proximity Read ↗

Olaparib-Resistant BRCA2MUT Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR/CHK1 Pathway for SurvivalSemantic proximity Read ↗

A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway.Semantic proximity Read ↗

The effect of AKT pathway inhibition on reversal of platinum resistance in ovarian cancer : a translational approachSemantic proximity Read ↗

Targeting the DNA damage response network as a therapeutical strategy in ovarian and pancreatic cancersSemantic proximity Read ↗

Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K.Semantic proximity Read ↗

Genomic Complexity and AKT Dependence in Serous Ovarian CancerSemantic proximity Read ↗

Positron emission tomography imaging of platinum resistant ovarian cancer and drug modulationSemantic proximity Read ↗

The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancerSemantic proximity Read ↗

Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2 - and Non– BRCA1/2 -Mutant CancersSemantic proximity Read ↗

Akt isoform specific effects in ovarian cancer progressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.